A 2026 cross-sectional schizophrenia study found no meaningful association between antipsychotic dose and Montreal Cognitive Assessment (MoCA) performance in young, clinically stable outpatients. Cognitive scores related more strongly to symptom burden, illness duration, education, and age at diagnosis than to daily or 1-year cumulative antipsychotic exposure.1 Research Highlights Daily dose was not linked to MoCA: …
Mukai et al.’s 499-person Phase 2b schizophrenia trial tested whether higher, sustained PDE10A inhibition could turn MK-8189 into a non-D2 antipsychotic; it did not. At week 6, MK-8189 missed the PANSS total endpoint at 16 mg (−2.8 points vs. placebo; 95% CI −8.3 to 2.6; P = 0.241) and 24 mg (−0.7 points; 95% CI …
Lurasidone is approved for schizophrenia and bipolar depression on the strength of acute trials that mostly reported a single number: the change in PANSS total score. A 2026 post-hoc analysis of the JEWEL Phase 3 trial pulls that number apart, looking separately at five symptom domains and at all 30 individual items of the PANSS …
Black Americans are diagnosed with schizophrenia-spectrum disorders at 2.42 times the rate of White Americans, and they also score higher on negative-symptom measures than White patients carrying the same diagnosis.2 A 2026 paper by Spann and colleagues asks why. Research Highlights Black Americans are diagnosed with schizophrenia-spectrum disorders at 2.42x the rate of White Americans, …